Krystal Biotech's Subsidiary Posts Durability Data For Fine Line, Wrinkles

Krystal Biotech Inc's KRYS subsidiary Jeune Aesthetics Inc, announced nine-month durability of effect in the extension cohort of the PEARL-1 study of KB301 to address the underlying biology of aging skin for improvement of fine lines and wrinkles.
Ten subjects from the PEARL-1 efficacy cohort were enrolled in the PEARL-1 extension cohort, an open-label study to assess the duration of effect below the zygomatic arch (the lower cheek area).
The extension cohort enrolled subjects who had received the high dose regimen of KB301 during the efficacy cohort in one or both of their lower cheeks.
Overall, data from the PEARL-1 extension cohort showed up to nine-month durability of effect following administration of high dose KB301.
The mean change in Subject Satisfaction Scores from baseline ranged from 1.6 to 1.85 points approximately seven to nine months after dosing.
In addition, Investigator Assessments for a clinically meaningful difference were also evaluated, with 70-76% of treated cheeks demonstrating a clinically meaningful difference approximately seven to nine months after KB301 dosing.
All reported adverse events were injection site-related, and the reported events were transitory and rated as mild or moderate.
Jeune is planning to initiate a Phase 2 study in 1H 2023 to assess the improvement of fine lines and wrinkles in challenging face areas.
Price Action: KRYS shares closed lower by 1.81% at $75.81 on Wednesday.

Overview Rating:

Speculative

0100